Since its establishment in 1981, Cambridge Life Sciences Ltd. has been committed to providing solutions and innovative healthcare products to the clinical diagnostic specialist.

The company’s early focus on novel biosensors resulted in a portfolio of patented PACE technologies that is now successfully exploited through collaboration with some of the world’s leading diagnostic companies. Immunosensor and biosensor developments continue with the involvement of the company in close co-operative projects with both commercial and academic groups.

Cambridge Life Sciences (CLS) also develops and manufactures immunoassay diagnostic kits based on the enzyme linked immunosorbent assay (ELISA) principles. It has developed two forms of ELISA: MELISA™, a range of kits based on a novel micropin solid phase system and AUTOZYME™, an ELISA range featuring liquid ready-to-use reagents that are designed and suitable for automated systems.

In addition, the company has developed assays for the detection and measurement of various drugs. Its market leading Paracetamol and Salicylate assays are testimony to its commitment to producing specific, rapid and robust testing methods.

Furthermore, it distributes products throughout the UK on behalf of various commercial partners including IMMCO and D-tek.

In December 2003 the management of CLS purchased 100% of the shares from the former parent company ALTANA Pharma AG. The divestment by ALTANA Pharma was driven by its intention to concentrate on its core pharmaceutical business. The deal will permit CLS to expand its key position in the Autoimmune kit market as well as continue to develop its propriety positions in immunosensors and nanotechnology for use in rapid screening kits.